Ref. Ares(2022)7920572 - 16/11/2022
Ref. Ares(2023)4265410 - 20/06/2023
From:
HOME NOTIFICATIONS D5
Sent:
mercredi 16 novembre 2022 16:27
To:
HOME NOTIFICATIONS D5
Subject:
Open Letter to the European Commission - Enabling reform efforts in the
Member States in the sense of effective drug policy
Attachments:
Nov2022_OpenLetter_EuropeanCommission_DrugPolicy.pdf; FW: Open Letter
to the European Commission - Enabling reform efforts in the Member States
in the sense of effective drug policy
From: Cansativa GmbH - Public Affai
rs <xxxxxxxxxxxxx@xxxxxxxxx.xx> Sent: Wednesday, November 16, 2022 8:00 AM
To: PARIAT Monique (HOME)
<xxxxxxx.xxxxxx@xx.xxxxxx.xx> Subject: Open Letter to the European Commission - Enabling reform efforts in the Member
States in the sense of effective drug policy
Dear Mrs. Pariat,
In the name of over 20 representatives from the industry and associations in the cannabis
industry I am sending you this open letter (please see attachment) and invitation for dialogue.
We, representatives of the European cannabis industry and associations, take note of the fact
that progressive approaches towards the use of adult-use cannabis have been prevailing in
international comparison for several years. In the European Union, more and more Member
States - including Malta, Luxembourg, the Czech Republic and the Netherlands - are embarking
to reform their formerly prohibitive drug policies in a result-oriented manner allowing for a new
cannabis policy framework covering all its use cases.
For a long time, attempts were made to restrict the cultivation, distribution and consumption of
cannabis through prohibitive and repressive drug policies. As a result, the use, availability and
THC potency of cannabis in the unregulated illicit market has been increasing, while
contamination continues to pose an unpredictable health threat to citizens in the EU[1]. Finally,
the failed drug policies of the past decades have led to organised crime generating billions in
revenue year after year.
Most recently, the government of the Federal Republic of Germany has presented a key issues
paper on how it intends to transfer the formerly illegal market for adult-use cannabis into a
regulated framework. These reforms are in no way contradictory to the global goals of improved
health protection. Therefore,
we would welcome a timely, in-depth evaluation of the capacities
of European drug policy under the global drug control treaties by the European Commission. By
sharing the German interpretation of those treaties,
the Commission will allow Member States
to implement forward-looking drug policies to reach the intentions of our global drug control
treaties far more effectively than the previous attempts of blanket prohibition.
In this comprehensive effort towards a new consensus, the Commission can rely on the support
of all stakeholders. We, the diverse European cannabis industry and associations, continuously
[1]
European Monitoring Centre for Drugs and Drug Addiction (2022), European Drug Report 2022: Trends and Developments, Publications Office
of the European Union, Luxembourg.
work towards increased research and knowledge sharing in the epistemic community. We see
ourselves as a resource for evidence-based policy making and are an ideal partner for
consultation and subject-matter evaluation. We trust that the EU-Commission will support all
endeavours to strengthen a paradigm shift in drug policy.
We assure you of our commitment to engage in constructive dialogue and contribute positively
to the critical debate.
Yours faithfully,
Tom Broockmann (Managing Director), ADREXpharma GmbH, Germany
Tej Virk (Director & CEO), Akanda Corp., United Kingdom
Lars Erik Råen (CEO), Balancial AS, Denmark
Dr. rer. medic. David Surjo (CCDO), Canify AG, Germany
Tim Henley (UK Commercial Manager), Cannim Group Pty Ltd, Australia
Stefan Jacker (COO), CanPharma GmbH, Germany
Ioana Freise (Head of Reg. & Public Affairs), Cansativa GmbH, Germany
Matthias Fischer (Managing Director), Canymed GmbH, Germany
Jan Simon (CEO), CZ Pharma s.r.o, Czech Republic
Dr. Constantin von der Groeben (Managing Director), DEMECAN GmbH, Germany
Thomas Schatton (CEO), Four 20 Pharma GmbH, Germany
Oliver Schultz (CCO), Grünhorn, Germany
Šárka Betke (Managing Director) High Five Group s.r.o., Czech Republic
Richard Balla (CEO), IMC adjupharm GmbH, Germany
Jonathan Lubosch-Haenisch (CEO), iuvo Therapeutics GmbH, Germany
Georg Wurth (CEO), German Cannabis Association, Germany
Dr. med. Jaschar Kermany (CEO), Kineo Medical GmbH, Germany
Michal Drdák (Business Director), Lagom Pharmatech s.r.o., Czech Republic
Nick Pateras (Managing Director), Materia Global, United Kingdom
Antonia Menzel (Director Public Affairs & Corp.Spokesperson) Sanity Group GmbH,
Germany
Luc Richner (Co-Founder and CEO), Vigia AG, Switzerland
Börge Diessel (Managing Director), WEECO Pharma GmbH, Germany
Ioana Freise Head of Regulatory & Public Affairs
T: +49 175 3866 201
xxxxx.xxxxxx@xxxxxxxxx.xx
Eingetragene Interessensvertreterin
Cansativa GmbH Hessenring 15i
64546 Mörfelden-Walldorf
T: +496105 96380 77
www.cansativa-group.com
Registergericht: AG Frankfurt am Main, HRB 108385
Geschäftsführer: Jakob Sons, Benedikt Sons
Die Cansativa GmbH ist mit der Nummer R002380 im Lobbyregister für die Interessenvertretung gegenüber dem
Deutschen Bundestag
und der Bundesregierung eingetragen und übt Interessenvertretung ausschließlich auf Grundlage des staatlichen
Verhaltenskodexes aus.
Document Outline
